A Study to Evaluate the da Vinci® Xi™ Surgical System in Nipple Sparing Mastectomy (NSM) Procedures

Overview

Información sobre este estudio

The purpose of this study is to evaluate the safety and effectiveness of the da Vinci Surgical Systems in Nipple Sparing Mastectomy procedures.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • Subject is female.
  • Subject has a BMI ≤ 29.
  • Subject is between 18 and 80 years of age.
  • Subject is a candidate for a unilateral or bilateral nipple sparing mastectomy procedure with mmediate reconstruction.
  • Subject is at increased risk for breast cancer and is seeking prophylactic NSM surgery.
  • Subject has no presence of occult cancer as confirmed by physical exam and by preoperative imaging per institution’s guidelines.  Known carriers of pathogenic BRCA1/2 mutations should have negative breast MRI.
  • Subject has breast ptosis ≤ Grade 2.
  • Subject has cup size ≤ C.
  • Subject is at low to moderate risk for anesthesia (ASA class I, II or III).
  • Subject is willing and able to provide written informed consent.
  • Subject is willing and able to comply with the study protocol requirements including follow up examinations up to 5 years (+/- 90 days) post operatively.

Exclusion Criteria:

  • Subject has current or prior history of ipsilateral in-situ or invasive breast carcinoma.
  • Subject has had previous breast surgery of the ipsilateral breast (excluding needle or core biopsies).
  • Subject has an inflammatory and/or infectious skin condition and/or unhealed wounds on the ipsilateral breast.
  • Subject has had chemotherapy for contralateral breast cancer within 3 weeks.
  • Subject has had previous radiation treatment to the ipsilateral breast/chest area.
  • Subject is planned to have other concomitant procedures (oophorectomy, hysterectomy, etc.).
  • Subject has a current history of smoking or has smoked within 1 month of screening.
  • Subject has hemoglobin A1C levels ≥ 8.
  • Subject has a high risk for anesthesia (ASA class ≥ IV) or significant medical comorbidities (i.e., cardiac, pulmonary and neurologic) that preclude longer anesthesia times.
  • Subject is contraindicated for general anesthesia or surgery.
  • Subject has a known bleeding or clotting disorder.
  • Subject is pregnant or suspected to be pregnant or is lactating.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Mara Piltin, D.O.

Abierto para la inscripción

Contact information:

Jennie Musty

(507) 266-0962

cancerclinicaltrialsreferrals@mayo.edu

Jacksonville, Fla.

Investigador principal de Mayo Clinic

James Jakub, M.D.

Abierto para la inscripción

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publicaciones

Publications are currently not available
.
CLS-20520126

Mayo Clinic Footer